Abstract

Background

Lower urinary tract symptoms are common among older men and 5-α reductase inhibitors (5-ARI) are a group of drugs recommended in treating these symptoms. The effect on prostate volume is mediated by a reduction in dihydrotestosterone; however, this reduction is counterbalanced by a 25% rise in serum testosterone levels. Therefore, 5-ARI use might have systemic effects and differentially affect bone mineral density, muscular mass and strength, as well as falls, all of which are major determinants of fractures in older men.

Methods

We conducted a nationwide cohort study of all Swedish men who used 5-ARI by comparing their risk of hip fracture, any type of fracture and of falls with matched control men randomly selected from the population and unexposed to 5-ARI.

Results

During 1 417 673 person-years of follow-up, 10 418 men had a hip fracture, 19 570 any type of fracture and 46 755 a fall requiring hospital care. Compared with unexposed men, current users of 5-ARI had an adjusted hazard ratio (HR) of 0.96 (95% CI 0.91–1.02) for hip fracture, an HR of 0.94 (95% CI 0.90–0.98) for all fracture and an HR of 0.99 (95% CI 0.96–1.02) for falls. Former users had an increased risk of hip fractures (HR 1.10, 95% CI 1.01–1.19).

Conclusion

5-ARI is safe from a bone health perspective with an unaltered risk of fractures and falls during periods of use. After discontinuation of 5-ARI, there is a modest increase in the rate of fractures and falls.
Introduction

Lower urinary tract symptoms (LUTS) are common among older men [1, 2]. Several guidelines recommend 5-α reductase inhibitors (5-ARIs) as a first treatment choice for LUTS in men with an enlarged prostate [3–5] since 5-ARIs reduce the volume of the prostate and thereby the risk of urinary retention and surgery [6–9]. The effect on prostate volume is mediated by a local pronounced reduction in dihydrotestosterone (DHT), which is the primary active androgen in the prostate [9, 10]. There is also a decrease in circulating DHT. However, this reduction is counteracted by a 25% rise in serum testosterone [9], which, by aromatization, might lead to higher circulating serum estradiol [11, 12]. Higher levels of circulating androgen and estrogen are positively associated with greater muscle and bone mass, improved postural balance and lower fracture risk in men [13–16]. In accordance, the risks of osteoporosis [17] and sarcopenia [18], low physical performance [19, 20], fall risk [19, 20], and fractures in some [13, 21], but not in all studies [22], are higher in men with low serum testosterone levels. Therefore, 5-ARI use might have systemic effects and differentially affect bone mineral density (BMD), muscular mass and strength, as well as falls, all of which are major determinants of fractures in older men [13, 19, 23–28]. These older men are especially vulnerable to consequent comorbidity and sustained high mortality after the fragility fracture event[29]. There are two clinically approved 5-ARIs on the pharmaceutical market: finasteride and dutasteride. The latter compound has a more complete suppression of the 5α-reductase isoenzymes and this treatment therefore leads to a more pronounced decrease in serum DHT concentrations [9, 30].

The potential net effect of 5-ARI treatment on BMD is at present unclear, with biological plausibility in either direction possible [17, 31]. Two small randomised clinical trials showed no certain effect by finasteride on BMD [32, 33].

Three previous attempts have sought to evaluate the relation between 5-ARI use and fracture risk by observational study designs. The approximately 20% relative reduction in risk of fracture observed with use of 5-ARI in one previous case-control study from the USA [34] was not confirmed in a Danish case-control study [35], or in a case-control study from the UK [36]. Importantly, given that elderly men are especially vulnerable to the often devastating consequences of fragility fractures, including high mortality rates [37–40], further analyses are warranted. None of the previous studies have evaluated rates of fracture with a cohort design or evaluated risk of falling, an important determinant of fracture risk, after initiation of 5-ARI. Any association between 5-ARI and fracture risk is probably modest and thus large studies are needed to establish sufficient power. We therefore conducted a nationwide cohort study of all Swedish men who used 5-ARI treatment and compared their future rate of hip fracture, any type of fracture and of falls with rates in men randomly selected from the population and unexposed to 5-ARI.

Methods

Study design

Data on exposure to finasteride or dutasteride, the two 5-ARIs currently in existence, were retrieved from The Swedish Prescribed Drug Register, which includes all prescriptions dispensed in Sweden since July 2005[41]. This register contains information on the amount and dose for each filled drug prescription as well as date of prescription and dispensing. All men older than 30 years who were exposed to 5-ARI at any time between 1 January 2006 to 31 December 2008 were included. In the cohort we additionally included from the Swedish Population Register randomly selected but frequency-matched men by year of birth and county of residence in a ratio of 5:1. These men were unexposed to previous use of 5-ARI and α-blockers.
and had not undergone a transurethral resection of their prostate (TUR-P; see below). Using the unique personal identity number assigned to each Swedish resident, the exposed and unexposed men were linked to a number of other nationwide health care registers and demographic databases [42, 43]. From 1987, the National Patient Register holds complete information, coded according to International Classification of Diseases (ICD-9 or ICD-10), on in-patient care and since 2001 information on out-patient hospital care. We identified such diagnoses and surgical procedures as TUR-P (KED 00–98) and surgical castrations (KFC 10, 15). From this register, we additionally identified outcome diagnoses: hip fracture ICD10 codes (S720-S722), any fracture (codes S12-S92) and any type of accidental fall (codes W00-W19). Men with a hip fracture diagnosis before 31 December 2005 were excluded. Endocrine treatment against prostate cancer and use of α-blockers was also identified from The Swedish Prescribed Drug Register. Because of convincing evidence connecting the metabolic syndrome to an increased risk not only to benign prostatic hyperplasia (BPH)/LUTS but also to poor physical performance and higher risk of fracture, we identified from the prescription register usage of medications related to the metabolic syndrome, such as statins and anti-hypertensive drugs [44–46]. We considered individual differences in comorbidities at baseline, identified from ICD codes from the National Patient Register, by classifying exposed and unexposed men into four categories of the Charlson weighted comorbidity index (CCI) [47]. The Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA) is a nationwide demographic database with data on socioeconomic factors [48]. From this database, we obtained information on educational level, which was categorised as low (≤ 9 years of school), medium (10–12 years) and high (≥ 13 years), which in Sweden corresponds to mandatory school, high school and college or university. The study was approved by the Research Ethics Board at Umeå University Hospital.

Statistics

We estimated age- and multivariate-adjusted hazard ratios (HRs) for risk of hip fracture, any fracture and falls by Cox proportional hazards regression using age as a time scale and with time-updated information on exposures and covariates. All men were followed from 1 January 2006 until date of event, date of death, emigration, start of endocrine treatment against prostate cancer or to the end of the observation period, i.e. 31 December 2011, whichever occurred first. Exposure of 5-ARI was first categorised into current and former use based on dates of first prescription and last prescription with duration of use defined by daily doses (DDD). Current users were analysed in categories (< 1, 1–2, 2–3, 3–4 and >4 years). Former users were separated into duration of use and time since last use by four categories: usage within the last year for a total duration of < 1 year, usage within the last year for a total duration of ≥ 1 year, usage more than 1 year ago with a total duration of use of <1 year and usage more than 1 year ago with a total duration of use for ≥1 year. In Sweden, the maximum dispensed doses at the pharmacy are 100 days. We monitored any discontinuation stepwise [49]. If no new prescription were collected at the pharmacy 90 days after the previous doses would have been consumed, we regarded this individual as a former user from that point and onwards. If there were any new prescription collected at the pharmacy after this period, he was again regarded as a current user.

To minimise potential bias the directed acyclic graph approach was used to identify a suitable multivariable model [50, 51]. Exposure to calcium antagonists, angiotensin converting enzyme inhibitors, angiotensin II inhibitors, β-blockers, statins, oral diabetes drugs, insulin and diuretics (subdivided into potassium-sparing, loop, thiazide and miscellaneous diuretics) were included in the models as separate binary time-dependent covariates (never user or ever user, defined as at least one prescription in the The Swedish Prescribed Drug Register). Additionally included in the
multivariable model were number of Charlson comorbidities (0, 1, 2, 3+) and education (high, medium, low). We also adjusted for time-dependent alpha-blocker use (ever, never) and TUR-P. Finally, we adjusted for previous fractures (0–1 and 1–5 years before start of follow-up) and previous hospitalisation due to fall (0–1 and 1–5 years before start of follow-up).

Table 1. Baseline characteristics for men exposed to 5 alpha reductase inhibitors (5-ARI) and selected non exposed men.

|                        | 5-ARI (n = 48 041) | Non exposed (n = 219 113) | All (n = 267 154) |
|------------------------|--------------------|----------------------------|-------------------|
| **Age, Mean (SD)**     | 72.1 (11.0)        | 72.4 (11.1)                | 72.4 (11.1)       |
| **Education level, n (%)** |                   |                             |                   |
| High                   | 10546 (22.0)       | 39664 (18.1)               | 50210 (18.8)      |
| Middle                 | 17394 (36.2)       | 76511 (34.9)               | 93905 (35.2)      |
| Low/Missing            | 20101 (41.8)       | 102938 (47.0)              | 123039 (46.1)     |
| **CCI, n (%)**         |                   |                             |                   |
| 0                      | 28398 (59.1)       | 136954 (62.5)              | 165352 (61.9)     |
| 1                      | 9416 (19.6)        | 39791 (18.2)               | 49207 (18.4)      |
| 2                      | 5387 (11.2)        | 22828 (10.4)               | 28215 (10.6)      |
| 3+                     | 4840 (10.1)        | 19540 (8.9)                | 24380 (9.1)       |
| **Calcium Antagonist, n (%)** |              |                             |                   |
| No                     | 39425 (82.1)       | 187810 (85.7)              | 227235 (85.1)     |
| Yes                    | 8616 (17.9)        | 31303 (14.3)               | 39919 (14.9)      |
| **ACE inhibitors, n (%)** |                  |                             |                   |
| No                     | 39039 (81.3)       | 183641 (83.8)              | 222680 (83.4)     |
| Yes                    | 9002 (18.7)        | 35472 (16.2)               | 44474 (16.6)      |
| **ANGII, n (%)**       |                   |                             |                   |
| No                     | 42015 (87.5)       | 198889 (90.8)              | 240904 (90.2)     |
| Yes                    | 6026 (12.5)        | 20224 (9.2)                | 26250 (9.8)       |
| **Statins, n (%)**     |                   |                             |                   |
| No                     | 35453 (73.8)       | 173554 (79.2)              | 209007 (78.2)     |
| Yes                    | 12588 (26.2)       | 45559 (20.8)               | 58147 (21.8)      |
| **Diabetes, n (%)**    |                   |                             |                   |
| No diabetes            | 42743 (89.0)       | 196586 (89.7)              | 239329 (89.6)     |
| Insulin                | 1548 (3.2)         | 7348 (3.4)                 | 8896 (3.3)        |
| Tablets                | 3750 (7.8)         | 15179 (6.9)                | 18929 (7.1)       |
| **Diuretics, n (%)**   |                   |                             |                   |
| No diuretics           | 36289 (75.5)       | 171115 (78.1)              | 207404 (77.6)     |
| Potassium-sparing- diuretics | 1131 (2.4)    | 4553 (2.1)                 | 5684 (2.1)        |
| Combined diuretics     | 1818 (3.8)         | 7470 (3.4)                 | 9288 (3.5)        |
| Loop diuretics         | 6237 (13.0)        | 25536 (11.7)               | 31773 (11.9)      |
| Thiazides              | 2566 (5.3)         | 10439 (4.8)                | 13005 (4.9)       |
| **Beta blockers, n (%)** |                  |                             |                   |
| No                     | 32033 (66.7)       | 155382 (70.9)              | 187415 (70.2)     |
| Yes                    | 16008 (33.3)       | 63731 (29.1)               | 79739 (29.8)      |
| **Alpha blockers, n (%)** |                  |                             |                   |
| No                     | 34916 (72.7)       | 219113 (100.0)             | 254029 (95.1)     |
| Yes                    | 13125 (27.3)       | 0 (0.0)                    | 13125 (4.9)       |
| **TURP, n (%)**        |                   |                             |                   |
| No                     | 45062 (93.8)       | 219113 (100.0)             | 264175 (98.9)     |
| Yes                    | 2979 (6.2)         | 0 (0.0)                    | 2979 (1.1)        |

SD, Standard deviation. ANGII, Angiotensin II Inhibitors. CCI, Charlson weighted comorbidity index. TURP, Transurethral resection of prostate.

doi:10.1371/journal.pone.0140598.t001
In a first sensitivity analysis we separately considered exposure to finasteride and dutasteride. Second, for a more accurate classification of duration of 5-ARI use, we restricted the analysis to men with their first exposure after 31 December 2005. If there were no prescription collected between 1 July to 31 December 2005, we regarded the individual as previously unexposed in that the drugs are normally dispensed every third month. If there were a prescription within this time frame, the individual was excluded from this specific sensitivity analysis.

Results

We included 48 041 men exposed to 5-ARI and 219 113 men not exposed to 5-ARI, with a combined mean age of 72 years. 5-ARI users had slightly more comorbidities and medication use associated with the metabolic syndrome Table 1.

During a total of 1 417 673 person-years of follow-up with a mean follow-up of 5.3 years, there were 10 418 with a hip fracture, 19 570 with any type of fracture and 46 755 with a fall requiring in-hospital care Table 2. Compared with unexposed men, current users of 5-ARI had a multivariate-adjusted HR of 0.96 (95% CI 0.91–1.02) for hip fracture, whereas former users had an increased HR of 1.10 (95% CI 1.01–1.19) Table 2. Similarly, when all fracture types were analysed, current users again had a modest tendency of a decreased rate of fracture with an adjusted HR of 0.94 (95% CI 0.90–0.98); former users had an increased rate of fracture with an HR of 1.10 (95% CI 1.04–1.17). Finally, men classified as current users had an unaltered risk of falls (HR 0.99, 95% CI 0.96–1.02) and former users had a slight increased risk of falls (HR 1.11, 1.07–1.15). These results were virtually unchanged if adjustment were done for previous fractures or falls.

Although men with current usage for more than 4 years conferred an HR of 0.92 (95% CI 0.83–1.02), there was no clear trend in risk of hip fracture associated with prolonged 5-ARI use.

Table 2. Risk of hip fractures, any fractures and falls by 5-ARI exposure.

|                        | Number of cases | Incidence | Univariate HR | 95% CI  | Multivariate HR | 95% CI | Multivariate HR | 95% CI |
|------------------------|-----------------|-----------|---------------|---------|-----------------|--------|-----------------|--------|
| **Hip fractures**       |                 |           |               |         |                 |        |                 |        |
| No 5-ARI               | 8045            | (7.24)    | 1.00 Ref.     |         | 1.00 Ref.       |        | 1.00 Ref.       |        |
| Current 5-ARI user     | 1536            | (8.05)    | 0.96 (0.91–1.01) |       | 0.96 (0.91–1.02) |       | 0.96 (0.91–1.02) |       |
| Former 5-ARI user      | 837             | (7.31)    | 1.08 (1.01–1.16) |       | 1.10 (1.01–1.19) |       | 1.10 (1.01–1.19) |       |
| **Any fractures**       |                 |           |               |         |                 |        |                 |        |
| No 5-ARI               | 15109           | (13.79)   | 1.00 Ref.     |         | 1.00 Ref.       |        | 1.00 Ref.       |        |
| Current 5-ARI user     | 2786            | (14.81)   | 0.96 (0.92–1.00) |       | 0.94 (0.90–0.98) |       | 0.93 (0.89–0.97) |       |
| Former 5-ARI user      | 1675            | (14.88)   | 1.14 (1.09–1.20) |       | 1.10 (1.04–1.17) |       | 1.10 (1.04–1.17) |       |
| **Falls**               |                 |           |               |         |                 |        |                 |        |
| No 5-ARI               | 35819           | (34.35)   | 1.00 Ref.     |         | 1.00 Ref.       |        | 1.00 Ref.       |        |
| Current 5-ARI user     | 6865            | (38.70)   | 1.04 (1.01–1.06) |       | 0.99 (0.96–1.02) |       | 0.98 (0.96–1.01) |       |
| Former 5-ARI user      | 4071            | (38.82)   | 1.18 (1.14–1.22) |       | 1.11 (1.07–1.15) |       | 1.11 (1.07–1.15) |       |

*Adjusted for previous use of Alpha blockers (Yes/No), Calcium antagonist (Yes/No), Angiotensin II antagonist (Yes/No), Beta blockers (Yes/No), ACE inhibitors (Yes/No), Lipid-modifying agents (Yes/No), Diabetes mellitus treatment (Insulin/tablets/No), Diuretics (Thiazides/Potassium-sparing agents/High ceiling diuretics/Combination diuretics/No), Previous TURP (Yes/No), Educational level (Low/medium/High), CCI (0,1,2,3+), Civil status (Single, not single).

*Adjusted for and previous fractures 0–1 years before start of follow up (Yes/No), previous fractures 1–5 years before start of follow up (Yes/No), previous hospitalisation due to fall 0–1 years before start of follow up (Yes/No), previous hospitalisation due to fall 1–5 years before start of follow up (Yes/No).

doi:10.1371/journal.pone.0140598.t002
exposure (Fig 1). Similarly, no clear trend could be established in the rates of any type of fracture by duration of use, although current use for 3–4 years led to an HR of 0.84 (95% CI 0.75–0.93) and current use for more than 4 years an HR of 0.91 (95% CI 0.85–0.99). Duration of current use was not related to the rates of falling.

Compared with never users of 5-ARI, men with former use that had ended their use within the last year had a risk close to unity for any of the outcomes. However, former use that had ended more than 1 year ago was, irrespective of duration of use, associated with a 20–30% higher rate of hip fracture, of any type of fracture and of falls.

Analysis restricted to men with a known start date of 5-ARI showed that these men (mean age 67 years) were 5 years younger than the full cohort. Expectedly, the proportion of men without comorbidity was higher than the original intact data set but the consumption of medication associated with the metabolic syndrome was reasonably the same Table 3. Although the numbers of events were lower, the results were comparable with the complete case analysis but with a slightly higher risk of fracture for current users Table 4. We could not identify any clear trends of hip fracture, any fracture or fall with prolonged 5-ARI exposure (Fig 2). For the sensitivity analysis, we found similar risk patterns between finasteride and dutasteride Table 5.
Table 3. Baseline characteristics of the study base for 5 alpha reductase inhibitors (5-ARI) exposed with known start date and selected non-exposed men.

|                  | 5-ARI (n = 19 614) | Non-exposed (n = 84 596) | All (n = 104 210) |
|------------------|--------------------|--------------------------|------------------|
| **Age, Mean (SD)** | 67.1 (11.0)        | 67.0 (11.3)              | 67.0 (11.2)      |
| **Education level, n (%)** |                   |                          |                  |
| High             | 4903 (25.0)        | 17923 (21.2)             | 22826 (21.9)     |
| Middle           | 7575 (38.6)        | 32361 (38.3)             | 39936 (38.3)     |
| Low/Missing      | 7136 (36.4)        | 34312 (40.6)             | 41448 (39.8)     |
| **CCI, n (%)**   |                    |                          |                  |
| 0                | 13046 (66.5)       | 58988 (69.7)             | 72034 (69.1)     |
| 1                | 3380 (17.2)        | 13240 (15.7)             | 16620 (15.9)     |
| 2                | 1716 (8.7)         | 6949 (8.2)               | 8665 (8.3)       |
| 3+               | 1472 (7.5)         | 5419 (6.4)               | 6891 (6.6)       |
| **Calcium Antagonist, n (%)** |             |                          |                  |
| No               | 16334 (83.3)       | 72766 (86.0)             | 89100 (85.5)     |
| Yes              | 3280 (16.7)        | 11830 (14.0)             | 15110 (14.5)     |
| **ACE inhibitors, n (%)** |                 |                          |                  |
| No               | 15961 (81.4)       | 70532 (83.4)             | 86493 (83.0)     |
| Yes              | 3653 (18.6)        | 14064 (16.6)             | 17717 (17.0)     |
| **ANGII, n (%)** |                    |                          |                  |
| No               | 17070 (87.0)       | 76054 (89.9)             | 93124 (89.4)     |
| Yes              | 2544 (13.0)        | 8542 (10.1)              | 11086 (10.6)     |
| **Statins, n (%)** |                   |                          |                  |
| No               | 14600 (74.4)       | 65876 (77.9)             | 80476 (77.2)     |
| Yes              | 5014 (25.6)        | 18720 (22.1)             | 23734 (22.8)     |
| **Diabetes, n (%)** |                   |                          |                  |
| No diabetes      | 17677 (90.1)       | 76324 (90.2)             | 94001 (90.2)     |
| Insulin          | 500 (2.5)          | 2559 (3.0)               | 3059 (2.9)       |
| Oral drugs       | 1437 (7.3)         | 5713 (6.8)               | 7150 (6.9)       |
| **Diuretics, n (%)** |                   |                          |                  |
| No diuretics     | 15815 (80.6)       | 68946 (81.5)             | 84761 (81.3)     |
| Potassium-sparing diuretics | 315 (1.6) | 1340 (1.6) | 1655 (1.6) |
| Combined diuretics | 650 (3.3) | 2716 (3.2) | 3366 (3.2) |
| Loop diuretics    | 1747 (8.9)         | 7358 (8.7)               | 9105 (8.7)       |
| Thiazides         | 1087 (5.5)         | 4236 (5.0)               | 5323 (5.1)       |
| **Beta blockers, n (%)** |                  |                          |                  |
| No               | 13685 (69.8)       | 61701 (72.9)             | 75386 (72.3)     |
| Yes              | 5929 (30.2)        | 22895 (27.1)             | 28824 (27.7)     |
| **Alpha blockers, n (%)** |                 |                          |                  |
| No               | 11906 (60.7)       | 84596 (100.0)            | 96502 (92.6)     |
| Yes              | 7708 (39.3)        | 0 (0.0)                  | 7708 (7.4)       |
| **TURP, n (%)**  |                      |                          |                  |
| No               | 18081 (92.2)       | 84596 (100.0)            | 102677 (98.5)    |
| Yes              | 1533 (7.8)         | 0 (0.0)                  | 1533 (1.5)       |

SD, Standard deviation. ANGII, Angiotensin II Inhibitors. CCI, Charlson weighted comorbidity index. TURP, Transurethral resection of prostate.
Discussion

Men with BPH and long-term current treatment with 5-ARI had no clear trend in the risk of hip fracture, any fracture or falling. Discontinuation of treatment—at least after a period of non-use—is related to higher rates of both fractures and falls.

The concerns about men’s bone health originate from the fairly broad effect that 5-ARI is known to have on several tissues. Two isozymes of 5-α reductase have been identified in humans (type I and type II). Type I is primarily in the liver but can also appear in bone and cartilage, whereas type II is mainly found in the male reproductive tissue [52–54]. The inhibition of 5-α reductase type II, caused by finasteride, lowers the intraprostatic levels of DHT. Because the primary androgen in prostate is DHT, this androgen plays an active role in BPH treatment [55]. With treatment, the circulating serum concentrations of DHT decrease by 70–85% [9, 10]. Dutasteride inhibits both 5-α reductase type I and type II, causing a decreased conversion of endogenous testosterone to DHT that leads to a 93–95% decrease in serum DHT concentrations [9, 30]. This decline in serum DHT is followed by a marked rise (25%) in serum testosterone but only 5% of serum testosterone produced in men undergo 5-α reduction to form the more potent androgen DHT [9, 56]. There is some evidence that human osteoblast-like cells express predominantly 5-α reductase type I and it is possible that local DHT production may play a role in human bone homeostasis [52]. This possibility is in part supported by findings that men with osteoporosis measured as low calcaneal BMD have significantly lower levels of DHT than their controls. Testosterone levels, on the other hand, were the same for both groups [17]. However, other aspects could also be found; for instance, men with 5-α-reductase-2 deficiency syndrome and normal testosterone levels have normal BMD [57]. Men with normal BMD but with low testosterone (less than 12 nmol/l) were treated during a 36-month period with either testosterone and finasteride, or testosterone with placebo, or placebo for

| Table 4. Risk of hip fractures, any fractures and falls by 5-ARI exposure with a known start date. |
|-----------------------------------------------|
| Number of cases | Incidence | Univariate | Multivariate & Multivariate# |
| | | HR | 95% CI | HR | 95% CI | HR | 95% CI |
|-----------------|----------|----------|----------|----------|----------|----------|----------|
| **Hip fracture** |          |          |          |          |          |          |          |
| No 5-ARI        | 1698     | (4.11)   | 1.00     | Ref.     | 1.00     | Ref.     | 1.00     | Ref.     |
| Current 5-ARI user | 314     | (5.22)   | 1.06     | (0.94–1.20) | 1.10     | (0.96–1.27) | 1.09     | (0.94–1.26) |
| Former 5-ARI user | 224     | (4.35)   | 1.07     | (0.93–1.23) | 1.13     | (0.95–1.35) | 1.12     | (0.94–1.33) |
| **Any fracture** |          |          |          |          |          |          |          |
| No 5-ARI        | 3839     | (9.40)   | 1.00     | Ref.     | 1.00     | Ref.     | 1.00     | Ref.     |
| Current 5-ARI user | 645     | (10.85)  | 1.02     | (0.94–1.11) | 1.02     | (0.93–1.13) | 1.01     | (0.92–1.11) |
| Former 5-ARI user | 550     | (10.85)  | 1.17     | (1.07–1.27) | 1.18     | (1.06–1.32) | 1.17     | (1.04–1.31) |
| **Falls**       |          |          |          |          |          |          |          |
| No 5-ar           | 10667    | (27.25)  | 1.00     | Ref.     | 1.00     | Ref.     | 1.00     | Ref.     |
| Current 5-ARI user | 1841    | (32.44)  | 1.10     | (1.05–1.16) | 1.04     | (0.98–1.10) | 1.02     | (0.96–1.08) |
| Former 5-ARI user | 1548    | (32.42)  | 1.20     | (1.14–1.27) | 1.12     | (1.05–1.20) | 1.11     | (1.04–1.19) |

#Adjusted for previous use of Alpha blockers (Yes/No), Calcium antagonist (Yes/No), Angiotsenin II antagonist (Yes/No), Beta blockers (Yes/No), ACE inhibitors (Yes/No), Lipid-modifying agents (Yes/No), Diabetes mellitus treatment (Insulin/Peroral/No), Diuretics (Thiazides/Potassium-sparing agents/High ceiling diuretics/Combination diuretics/No), Previous TURP (Yes/No), Educational level (Low/medium/High), CCI (0,1,2,3+), Civil status (Single, not single)

#Adjusted for and previous fractures 0–1 years before start of follow-up (Yes/No), previous fractures 1–5 years before start of follow-up (Yes/No), previous hospitalisation due to fall 0–1 years before start of follow-up (Yes/No), previous hospitalisation due to fall 1–5 years before start of follow-up (Yes/No).

doi:10.1371/journal.pone.0140598.t004
testosterone and placebo for finasteride. BMD increased equally and significantly for both groups on testosterone and was unchanged for men on placebo [58]. One possible explanation for these findings is that in tissues with low 5-α-reductase activity, such as muscle and bone, intratissue DHT concentrations are very low relative to testosterone and can be discontinued and the androgen effect is maintained by testosterone [59].
In our study men who discontinued treatment of 5-ARI more than 1 year ago had an increased risk of falls, as well as of hip or any type of fractures. We have no information on why the men terminated their 5-ARI medication. Theoretically, it could both be mediated by increased frailty rendering permanent catheter treatment or a perceived lack of effect of the medicine. If the latter were the case, this could lead to increased micturition problems and nocturia is indeed a risk factor for hip fracture [60–62]. The fact that it took 1 year before these men increased their risk of fall and fractures might be explained by the slow progress in prostate volume after discontinuation of 5-ARI therapy, making it appear as a delayed effect.

From The Proscar long-term efficacy and safety study (PLESS), the relative risk (RR) of an osteoporotic (hip, wrist and vertebrae) fracture in the entire cohort was 0.95 (95% CI 0.45–2.01, p = 0.89). There was also a tendency of an increased risk of any fracture (RR 1.33; 95% CI 0.92–1.91; p = 0.03) [32]. The risk of falling was not studied.

Epidemiological attempts to study the relation between 5-ARI use and hip fracture risk have been few. In a case-control study from the USA, the use of 5-ARI was compared in 7076 hip fracture cases and a similar number of controls. Only 1.8% of the participants were exposed to finasteride, corresponding to 108 cases and 141 controls [34]. The crude odds ratio was 0.77, 95% CI 0.59–1.00, p = 0.04, but the estimate was not attenuated after multivariable adjustment, which, however, did not include body mass index or markers of the metabolic syndrome. No trend was observed with duration of 5-ARI use. Moreover, no association between a diagnosis

| Table 5. Sensitivity analysis when hip fracture, any fracture and falls are divided in men exposed to finasteride or dutasteride, shown as a multivariate adjusted hazard ratio (HR) with 95% confidence intervals (CI). |
|---------------------------------|----------------|-----------------|-----------------|----------------|
| **Finasteride**                | **Number of cases** | **Incidence** | **HR** | **95% CI** |
| **Hip fracture**               |                  |                |       |            |
| No 5-ARI                       | 8026             | (7.24)         | 1.00  | Ref.       |
| Current 5-ARI user             | 1296             | (8.67)         | 0.97  | (0.91–1.03)|
| Former 5-ARI user              | 637              | (7.80)         | 1.12  | (1.03–1.23)|
| **Any fracture**               |                  |                |       |            |
| No 5-ARI                       | 15069            | (13.79)        | 1.00  | Ref.       |
| Current 5-ARI user             | 2312             | (15.70)        | 0.94  | (0.89–0.98)|
| Former 5-ARI user              | 1246             | (15.52)        | 1.11  | (1.04–1.18)|
| **Falls**                      |                  |                |       |            |
| No 5-ARI                       | 35713            | (34.36)        | 1.00  | Ref.       |
| Current 5-ARI user             | 5577             | (40.23)        | 0.98  | (0.95–1.01)|
| Former 5-ARI user              | 2942             | (39.32)        | 1.10  | (1.05–1.15)|
| **Dutasteride**                |                  |                |       |            |
| **Hip fracture**               |                  |                |       |            |
| No 5-ARI                       | 7828             | (7.34)         | 1.00  | Ref.       |
| Current 5-ARI user             | 176              | (6.14)         | 0.98  | (0.84–1.14)|
| Former 5-ARI user              | 164              | (5.84)         | 0.97  | (0.82–1.15)|
| **Any fracture**               |                  |                |       |            |
| No 5-ARI                       | 14639            | (13.92)        | 1.00  | Ref.       |
| Current 5-ARI user             | 342              | (12.05)        | 0.92  | (0.82–1.03)|
| Former 5-ARI user              | 356              | (12.91)        | 0.99  | (0.88–1.11)|
| **Falls**                      |                  |                |       |            |
| No 5-ARI                       | 34510            | (34.50)        | 1.00  | Ref.       |
| Current 5-ARI user             | 896              | (32.82)        | 0.93  | (0.87–1.00)|
| Former 5-ARI user              | 943              | (36.52)        | 1.03  | (0.95–1.11)|

PLOS ONE | DOI:10.1371/journal.pone.0140598 October 15, 2015 10 / 15

doi:10.1371/journal.pone.0140598.t005
of BPH or BPH surgery and the odds of hip fractures was found. In a Danish case-control study 9719 males with any fracture were included and age-matched with 29 156 controls. Use of 5-ARI was present among 6.8 of the cases and 6.2% of the controls. No altered risk of fractures for men exposed to 5-ARI was observed [35]. Similarly, in a hip fracture case-control study performed in the UK few had been under 5-ARI treatment. Thus, only 20 (0.4%) of the 4571 cases and 10 (0.2%) of the 4571 controls had used finasteride, rendering a low precision in the risk estimates. In neither of these studies was the risk of falling studied.

The present study has limitations that merit discussion. First, we used an observational design and the selection process as to why the men initiated and ended therapy is difficult to capture using register information. Comorbidity information was considered in the analysis but the possibility of residual confounding cannot be excluded. Second, our follow-up period was short to intermediate with a maximum follow-up of 6 years. Third, body stature was not measured and components of the metabolic syndrome were not actually measured. Instead, we used specific medications as surrogate measures for metabolic syndrome.

Strengths of this study are the nationwide and therefore strictly population-based approach and the cohort design with time-dependent exposure analysis. The use of the unique personal identity number (Swedish: personnummer) that is given to all Swedish residents provided complete linkage between registers, with the consequence of virtually no problem caused by loss of participants. In addition, we were able to adjust our results for existing comorbidities, medication use and education level as one aspect of socioeconomic status.

Conclusions

We conclude that 5-ARI is safe for men’s bone health, primarily because there is no change in the risk pattern for fractures and falls during periods of use. After discontinuation of 5-ARI, there is a modest increase in the rate of fractures and falls. However, the underlying cause of these associations cannot be determined by our study design.

Acknowledgments

This study was funded by Futurum, Jönköping County Council, Sweden. Futurum had no part in the collection, management, analysis, interpretation of the data and not in preparation, review, or approval of the manuscript.

Author Contributions

Conceived and designed the experiments: DR HG PS KM. Performed the experiments: DR HG PS KM. Analyzed the data: DR HG PS KM. Contributed reagents/materials/analysis tools: DR HG PS KM. Wrote the paper: DR HG PS KM. Financial support: DR PS KM.

References

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991; 338(8765):469–71. Epub 1991/08/24. doi: 0140-6736(91)90543-X [pii]. PMID:1714529.
2. Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community based cohort. The Journal of urology. 2000; 163(1):107–13. Epub 1999/12/22. doi: S0022-5347(05)67984-0 [pii]. PMID:10604326.
3. Oelke M, Bachmann A, Descazzeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013; 64(1):118–40. doi: 10.1016/j.eururo.2013.03.004 PMID:23541336.
4. Auanet.org website. Available: http://www.auanet.org/common/pdf/education/clinical-guidance/ Benign-Prostatic-Hyperplasia.pdf. Accessed 2014 Sep 1.
Orwoll E, Lambert LC, Marshall LM, Blank J, Barrett-Connor E, Cauley J, et al. Endogenous testosterone.

Ilangovan R, Sittadjody S, Balaganesh M, Sivakumar R, Ravi Sankar B, Balasubramanian K, et al. Fractures, Falls and 5α-Reductase Inhibitor Use

Schaap LA, Pluijm SM, Smit JH, van Schoor NM, Visser M, Gooren LJ, et al. The association of sex hormones with poor mobility, low muscle strength and incidence of falls among older men and women. Clinical endocrinology. 2005; 63(2):152–60. doi: 10.1111/j.1365-2265.2005.02315.x PMID: 16060908.

LeBlanc ES, Nielsen CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. The Journal of clinical endocrinology and metabolism. 2009; 94(9):3337–46. doi: 10.1210/jc.2009-0206 PMID: 19584177; PubMed Central PMCID: PMC2741717.

Barrett-Connor E, Laughlin GA, Li H, Nielsen CM, Wang PY, Dam TT, et al. The association of concurrent vitamin D and sex hormone deficiency with bone loss and fracture risk in older men: the Nice.org website. Available: http://www.nice.org.uk/guidance/cg97/evidence/cg97-lower-urinary-tract-symptoms-full-guideline3.
osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2012; 27(11):2306–13. doi: 10.1002/jbmr.1697 PMID: 22777902; PubMed Central PMCID: PMC3474871.

23. Jarvinen TL, Sievanen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. Bmj. 2008; 336(7636):124–6. Epub 2008/01/19. doi: 10.1136/bmj.39428.470752.AD PMID: 18202065; PubMed Central PMCID: PMC2206310.

24. Nevitt MC, Cummings SR, Kidd S, Black D. Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA. 1989; 261(18):2663–8. Epub 1989/05/12. PMID: 2709546.

25. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. The New England journal of medicine. 1988; 319(26):1701–7. Epub 1988/12/29. doi: 10.1056/NEJM198812293192604 PMID: 21346095.

26. Tideiksaar R. Preventing falls: how to identify risk factors, reduce complications. Geriatrics. 1996; 51(2):43–6; 9–50. 3, quiz 4–5. Epub 1996/02/01. PMID: 8631531.

27. Auyeung TW, Lee JS, Kwok T, Leung J, Ohlsson C, Vandenput L, et al. Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men. European journal of endocrinology / European Federation of Endocrine Societies. 2011; 164(5):811–7. Epub 2011/02/25. doi: 10.1530/EJE-10-0952 PMID: 21346095.

28. Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushner M, Rockwood AL, et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008; 168(1):47–54. Epub 2008/01/16. doi: 10.1001/archinternmed.2007.2 PMID: 18195195.

29. Michaelsson K, Nordstrom P, Nordstrom A, Garmo H, Byberg L, Pedersen N, et al. Impact of hip fracture on mortality: a cohort study in hip fracture discordant identical twins. J Bone Miner Res. 2014; 29(2):424–31. Epub 2013/07/04. doi: 10.1002/jbmr.2020 PMID: 23821464.

30. Androile GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. The Journal of urology. 2004; 172(3):915–9. Epub 2004/08/18. doi: S0022-5347(04)61521-2 [pii]. doi: 10.1097/01.juo.0000136430.37245.b9 PMID: 15310997.

31. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. The Journal of clinical endocrinology and metabolism. 1997; 82(8):2386–90. Epub 1997/08/01. PMID: 9253305.

32. Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, et al. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. The Journal of urology. 2002; 167(5):2105–8. PMID: 11956450.

33. Amory JK, Anawalt BD, Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. The Journal of urology. 2008; 179(6):2333–8. Epub 2008/01/14. doi: 10.1097/JUO.0b013e3181667e67 PMID: 18423697; PubMed Central PMCID: PMC2884818.

34. Jacobsen SJ, Cheetham TC, Haque R, Shi J, Loo RK. Association between 5-alpha reductase inhibition and risk of hip fracture. Jama. 2008; 300(14):1660–4. Epub 2008/10/09. doi: 10.1001/jama.300.14.1660 [pii]. doi: 10.1001/jama.300.14.1660 PMID: 18840839.

35. Vestergaard P, Rejmark L, Mosekilde L. Risk of fractures associated with treatment for benign prostate hyperplasia in men. Osteoporos Int. 2011; 22(2):731–7. Epub 2010/06/17. doi: 10.1007/s00198-010-1320-4 PMID: 20552327.

36. Souverein PC, Van Staa TP, Egberts AC, De la Rosette JJ, Cooper C, Leufkens HG. Use of alpha-blockers and the risk of hip/femur fractures. Journal of internal medicine. 2003; 254(6):548–54. PMID: 14641735.

37. Brauer CA, Coka-Perraino M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA. 2008; 300(14):1573–9. Epub 2008/10/15. doi: 10.1001/jama.300.14.1573 PMID: 18840839.

38. Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De Laet C. The burden of hospitalised fractures in Sweden. Osteoporos Int. 2005; 16(2):222–8. Epub 2004/07/03. doi: 10.1007/s00198-004-1886-2 PMID: 15232678.

39. Hopkins RB, Pullenayegum E, Geooe R, Adachi JD, Papaioannou A, Leslie WD, et al. Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int. 2012; 23(3):321–7. Epub 2011/05/11. doi: 10.1007/s00198-011-1652-8 PMID: 21557096.

40. Haentjens P, Magaziner J, Colom-Emerich CS, Vanderschueren D, Millesen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Annals of internal medicine.
41. Socialstyrelsen. National Board of Health and Welfare: The Prescribed Drug Register (In Swedish).

42. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekborn A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009; 24(11):659–67. Epub 2009/06/09. doi: 10.1007/s10654-009-9350-y PMID: 19504049; PubMed Central PMCID: PMC2773709.

43. Socialstyrelsen. The National Patient Register. Available: http://www.socialstyrelsen.se/register/

44. Eveson-Rose SA, Paudel M, Taylor BC, Dam T, Cawthon PM, Leblanc E, et al. Metabolic syndrome and physical performance in elderly men: the osteoporotic fractures in men study. J Am Geriatr Soc. 2011; 59(8):1376–84. Epub 2011/08/03. doi: 10.1111/j.1532-5415.2011.03518.x PMID: 21806561; PubMed Central PMCID: PMC3545517.

45. Moul S, McVary KT. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol. 2010; 20(1):7–12. Epub 2009/11/12. doi: 10.1097/MOU.0b013e3283336f3f PMID: 19904208.

46. von Muhlen D, Safii S, Jassal SK, Svartberg J, Barrett-Connor E. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int. 2007; 18(10):1337–44. Epub 2007/05/12. doi: 10.1007/s00198-007-0385-1 PMID: 17492393.

47. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373–83. Epub 1987/01/01. PMID: 3558716.

48. Hagel E, Garmo H, Bill-Axelson A, Srebrny M, Johansson JE, Adolfsson J, et al. PCBaSe Sweden: A register-based resource for prostate cancer research. Scand J Urol Nephrol. 2009. 1–8. PMID: 19489392.

49. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. The New England journal of medicine. 1985; 312(25):1604–8. doi: 10.1056/NEJM198506203122504 PMID: 4000199.

50. VanderWeele TJ, Hernan MA, Robins JM. Causal directed acyclic graphs and the direction of unmeasured confounding bias. Epidemiology. 2008; 19(5):720–8. doi: 10.1097/EDE.0b013e3181810e29 PMID: 18633331.

51. Shrier I, Platt RW. Reducing bias through directed acyclic graphs. BMC medical research methodology. 2008; 8:70. Epub 2008/11/01. doi: 10.1186/1471-2288-8-70 PMID: 18973665; PubMed Central PMCID: PMC2601045.

52. Issa S, Schnabel D, Feix M, Wolf L, Schaefer HE, Russell DW, et al. Human osteoblast-like cells express predominantly steroid 5 alpha-reductase type 1. The Journal of clinical endocrinology and metabolism. 2002; 87(12):5401–7. Epub 2002/12/06. PMID: 12466325.

53. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J Clin Invest. 1992; 89(1):293–300. Epub 1992/01/01. doi: 10.1172/JCI116574 PMID: 1345916; PubMed Central PMCID: PMC442847.

54. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 1993; 92(2):903–10. Epub 1993/08/01. doi: 10.1122/JCI116665 PMID: 7688765; PubMed Central PMCID: PMC294929.

55. van der Sluis TM, Meulman EJ, van Moorselaar RJ, Bui HN, Blankenstein MA, Heijboer AC, et al. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. BJU international. 2012; 109(2):183–8. Epub 2011/10/09. doi: 10.1111/j.1464-410X.2011.10652.x PMID: 21992404.

56. Ito T, Horton R. The source of plasma dihydrotestosterone in man. J Clin Invest. 1971; 50(8):1621–7. Epub 1971/08/01. doi: 10.1172/JCI106650 PMID: 5097569; PubMed Central PMCID: PMC442061.

57. Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J. Bone mineral density in the complete androgen insensitivity and Salpha-reductase-2 deficiency syndromes. The Journal of clinical endocrinology and metabolism. 2006; 91(8):3017–23. Epub 2006/06/01. doi: jc.2005-2809 [pii]. doi: 10.1210/jc.2005-2809 PMID: 16735493.

58. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. The Journal of clinical endocrinology and metabolism. 2004; 89(2):503–10. Epub 2004/02/07. PMID: 14764753.

59. Bhasin S, Travison TG, Storer TW, Lakshman K, Kaushik M, Mazer NA, et al. Effect of testosterone supplementation with and without a dual Salpha-reductase inhibitor on fat-free mass in men with

2010; 152(6):380–90. Epub 2010/03/17. doi: 10.1059/0003-4819-152-6-201003160-00008 PMID: 20231569; PubMed Central PMCID: PMC3010729.
suppressed testosterone production: a randomized controlled trial. Jama. 2012; 307(9):931–9. Epub 2012/03/08. doi: 307/9/931 [pii]. doi: 10.1001/jama.2012.227 PMID: 22396515.

60. Asplund R. Hip fractures, nocturia, and nocturnal polyuria in the elderly. Arch Gerontol Geriatr. 2006; 43(3):319–26. Epub 2006/02/07. doi: 10.1016/j.archger.2005.12.002 PMID: 16457897.

61. Temml C, Ponholzer A, Gutiahr G, Berger I, Marszalek M, Madersbacher S. Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn. 2009; 28(8):949–52. Epub 2009/03/21. doi: 10.1002/nau.20712 PMID: 19301408.

62. Jensen J, Lundin-Olsson L, Nyberg L, Gustafson Y. Falls among frail older people in residential care. Scand J Public Health. 2002; 30(1):54–61. Epub 2002/04/04. PMID: 11928835.